Abstract
Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder with systemic manifestations such as lymphadenopathy, fever and microcytic anemia. Over-production of interleukin-6 (IL-6) has been speculated to be a key event in the pathogenesis of this disorder. IL-6 is known to stimulate hepatic expression of hepcidin, a central regulator of body iron homeostasis. We developed a SELDI-TOF mass spectrometry-based semi-quantitative method for serum hepcidin-25 (
. | Case 1 . | Case 2 . | Case 3 . | Case 4 . | Case 5 . |
---|---|---|---|---|---|
. | Pre/Day14 . | Pre/Day14 . | Pre/Day14 . | Pre/Day14 . | Pre/Day14 . |
Hepcidin-25 (ng/ml) | 44.8/2.2 | 55.5/24.6 | 14/0.8 | 43.5/1.5 | 256/166 |
CRP (mg/dl) | 24.3/5.4 | 11.7/4.1 | 16.9/3.6 | 7.6/0.2 | 11.9/6.8 |
Hb (g/dl) | 5.7/9.2 | 10.2/11.2 | 6.3/7.9 | 8.2/9.4 | 6.5/7.4 |
. | Case 1 . | Case 2 . | Case 3 . | Case 4 . | Case 5 . |
---|---|---|---|---|---|
. | Pre/Day14 . | Pre/Day14 . | Pre/Day14 . | Pre/Day14 . | Pre/Day14 . |
Hepcidin-25 (ng/ml) | 44.8/2.2 | 55.5/24.6 | 14/0.8 | 43.5/1.5 | 256/166 |
CRP (mg/dl) | 24.3/5.4 | 11.7/4.1 | 16.9/3.6 | 7.6/0.2 | 11.9/6.8 |
Hb (g/dl) | 5.7/9.2 | 10.2/11.2 | 6.3/7.9 | 8.2/9.4 | 6.5/7.4 |
Author notes
Disclosure:Ownership Interests: N.T. doubles as President of Medical Care Proteomics Biotechnology Co.,Ltd. Ishikawa-ken, Japan. Research Funding: This work was supported in part by a grant-in aid for scientific research from the Ministry of Education, Science, Sports and Culture of Japan and a grant from Takeda Science Foundation.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal